What is the Poly Medicure PE ratio today?
Poly Medicure's PE ratio is 47.0 at the 29 October 2026 close (₹1,461.90 a share): a market capitalisation of ₹14,818 crore divided by consolidated net profit attributable to shareholders of ₹315 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹322 crore) it is 46.0.
What is the Poly Medicure PB ratio (price to book value)?
Poly Medicure's price-to-book (PB) ratio is 4.77 at the 29 October 2026 close: a market capitalisation of ₹14,818 crore divided by shareholders' equity (book value) of ₹3,106 crore on 31 March 2026. That is a book value of ₹306.45 per share against a share price of ₹1,461.90.
What is the Poly Medicure book value per share?
Poly Medicure's book value per share was ₹306.45 on 31 March 2026: shareholders' equity of ₹3,106 crore divided by the 10.14 crore shares in issue, up 12.3% from ₹272.95 a year earlier. The share price at the 29 October 2026 close was ₹1,461.90.
What is the Poly Medicure market cap?
Poly Medicure's market capitalisation was ₹14,818 crore at the 29 October 2026 close: 10.14 crore shares at ₹1,461.90 each.
Is Poly Medicure debt free?
No. Poly Medicure had borrowings of ₹342 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.11. Its cash and current investments were ₹827 crore, so it held net cash of ₹485 crore.
What is the Poly Medicure EPS?
Poly Medicure's basic earnings per share (EPS) were ₹31.79 in FY26, against ₹34.13 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹31.09.
What is the Poly Medicure debt to equity ratio?
Poly Medicure's debt-to-equity ratio was 0.11 on 31 March 2026: borrowings of ₹342 crore against total equity of ₹3,149 crore. A year earlier, on 31 March 2025, it was 0.06.
What is the Poly Medicure net worth?
Poly Medicure's net worth — shareholders' equity in its consolidated balance sheet — was ₹3,106 crore on 31 March 2026, up 12.3% from ₹2,766 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹14,818 crore at the 29 October 2026 close.
What is the Poly Medicure dividend yield?
Poly Medicure's dividend yield is 0.24% at the 29 October 2026 close: dividends of ₹3.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,461.90. They were ₹3.50 on 28 August 2026.
What is the Poly Medicure ROE and ROCE?
In FY26, Poly Medicure's return on equity (ROE) was 11.0% and its return on capital employed (ROCE) was 10.6%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 16.0% and ROCE 17.1%.
What is the Poly Medicure shareholding pattern?
On 30 September 2026, Poly Medicure's shares were held by promoters 62.42%, foreign portfolio investors (FII/FPI) 5.35%, domestic institutions (DII) 15.90% (including mutual funds at 9.77%) and retail and other non-institutional investors 16.33%. Over the year, FII holding was down 4.42 percentage points from 9.77% and DII holding was up 2.36 percentage points from 13.54%.
What are the Poly Medicure latest quarterly results?
Poly Medicure's latest results are for Q1 FY27 (April–June 2026), filed on 7 August 2026: consolidated net profit attributable to shareholders ₹86 crore, down 7.6% from ₹93.1 crore in Q1 FY26; revenue from operations ₹525 crore, up 30.3% year on year.
What is the Poly Medicure dividend in 2026 and its record date?
In 2026, Poly Medicure has declared one dividend: ₹3.50 with record date 29 August 2026 and ex-date 28 August 2026.
What is the Poly Medicure promoter holding?
Promoters held 62.42% of Poly Medicure on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Poly Medicure free cash flow?
In FY26, Poly Medicure generated ₹241 crore of cash from operations and spent ₹308 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹67.7 crore. In FY25 it was −₹83.9 crore.
What is the Poly Medicure revenue and profit in FY26?
In FY26 (April 2025–March 2026), Poly Medicure's consolidated net profit attributable to shareholders was ₹322 crore, down 4.8% from ₹339 crore in FY25, on revenue from operations of ₹1,875 crore (up 12.3%). Over three years, from FY23, net profit was up 79.7%.
When are the Poly Medicure next results?
Poly Medicure will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.
Poly Medicure vs Pfizer: how do they compare?
In FY26, Poly Medicure earned net profit attributable to shareholders of ₹322 crore on revenue of ₹1,875 crore, against ₹722 crore on ₹2,520 crore for Pfizer. Poly Medicure's operating margin was 17.4% (Pfizer 33.6%) and its return on equity 11.0% (Pfizer 17.2%). At the 29 October 2026 close, Poly Medicure's market capitalisation was ₹14,818 crore against ₹17,201 crore for Pfizer, and its PE ratio on FY26 profit 46.0 against 23.8.
How does Poly Medicure compare with its peers?
On FY26 consolidated figures, against Pfizer, Rainbow Childrens Medicare and Onesource Specialty Pharma: Poly Medicure's operating margin of 17.4% is the third highest of the four (Pfizer 33.6%, Rainbow Childrens Medicare 23.1%, Onesource Specialty Pharma 1.8%; peer average 19.5%); its return on equity of 11.0% is the third highest of the four (Pfizer 17.2%, Rainbow Childrens Medicare 17.9%, Onesource Specialty Pharma −1.3%; peer average 11.3%).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
